Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


AstraZeneca asthma drug fails in phase III trial

Interleukin 13 cytokine protein 3D illustration

Source: molekuul_be/Shutterstock

The monoclonal antibody, tralokinumab, which blocks Interleukin 13 cytokine protein (pictured), failed to reduce the annual rate of asthma exacerbations

An experimental drug being tested as a treatment for severe asthma by pharmaceutical company AstraZeneca has failed to meet its primary endpoint of significantly reducing the annual rate of asthma exacerbations in the first of two phase III studies, the company has announced.

The drug, tralokinumab, is an anti-interleukin-13 human monoclonal antibody, which blocks the interleukin-13 (IL-13) protein.

The trial, STRATOS 1, evaluated the efficacy and safety of tralokinumab in reducing the rate of asthma exacerbations in adults and adolescents with severe asthma, inadequately controlled despite receiving inhaled corticosteroids plus long-acting beta2-agonist.

While a clinically relevant reduction in asthma exacerbations was not observed in asthma patients overall, a reduction in exacerbations was seen in a sub-population of patients. This sub-group of patients had an elevated biomarker associated with increased IL-13 activity and will now be the focus for the future analysis of the second trial, STRATOS 2, results of which are expected later in 2017.

Sean Bohen, executive vice president, global medicines development and chief medical officer at AstraZeneca, says: “Severe asthma is a heterogeneous disease with significant unmet needs and we will now await the STRATOS 2 results in the second half of 2017 to explore the potential to treat a sub-group of uncontrolled asthma patients with tralokinumab.”

A drug being developed by competitor company Roche called lebrikizumab, which blocks the same IL-13 protein, also produced disappointing phase III trial results last year.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202768

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Interleukin 13 cytokine protein 3D illustration

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.